Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health and other institutions conclude that new technology could soon help doctors slash that number

News | Heart Valve Technology

New Technology Promises to Revolutionize Valvular Heart Disease Care

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

April 01, 2024

Analysis signals higher risk of hypertension among females resting less than seven hours compared with males, according to data to be presented at the upcoming American College of Cardiology Annual Scientific Session & Expo, ACC.24, to be held April 6-8 in Atlanta, GA.

News | Hypertension

Getting Too Little Sleep Linked to High Blood Pressure

April 1, 2024 — Sleeping fewer than seven hours is associated with a higher risk of developing high blood pressure over ...

April 01, 2024

While likelihood of cardiomyopathy grows over time, the overall risk remains low

News | Pediatric Cardiology

ADHD Stimulants May Increase Risk of Heart Damage in Young Adults

March 29, 2024 — Young adults who were prescribed stimulant medications for attention-deficit/hyperactivity disorder (AD ...

March 29, 2024

V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at ACC24

News | Heart Failure

V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session and Expo

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

March 29, 2024

Findings from the admIRE study – freedom from atrial arrhythmia recurrence at 12 months – support the submission of the VARIPULSE Platform among U.S. patients

News | Atrial Fibrillation

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

March 28, 2024

WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone

News | FDA

FDA Approves Merck’s WINREVAIR, a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension

March 27, 2024 — Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug ...

March 27, 2024

Esperion announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes subgroup analyses as poster presentations at ACC24

News | Cardiovascular Clinical Studies

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session and Industry Expert Theatre to be Presented at ACC.24

March 26, 2024 — Esperion announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL ...

March 26, 2024

Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.

News | ACC

Bristol Myers Squibb to Present Data on CAMZYOS (mavacamten) for obstructive hypertrophic cardiomyopathy (HCM) at American College of Cardiology Annual Scientific Session, ACC.24

March 26, 2024 — Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II ...

March 26, 2024

Here is a look at the education and special events planned for the ACC24 73rd Annual Scientific Session & Expo, April 6-8 in Atlanta

Feature | ACC | By Melinda Taschetta-Millane

American College of Cardiology (ACC24) Show Preview: Advancing Cardiovascular Care for All

The American College of Cardiology (ACC) has announced key educational and programming highlights for its ACC 73rd ...

March 25, 2024

Abbott announced the first patient has been enrolled in the ENVISION investigational device exemption (IDE) clinical trial.

News | Cardiovascular Clinical Studies

Abbott Announces First Procedures in ENVISION Trial of Navitor TAVI System to Treat Patients With Severe Aortic Stenosis

March 25, 2024 — Abbott announced the first patient has been enrolled in the ENVISION investigational device exemption ...

March 25, 2024

A bioelectronic mesh, studded with graphene sensors (red), can measure the electrical signal and movement of cardiac tissue (purple and green) at the same time.

News | Heart Failure

UMass Amherst Engineers Create Bioelectronic Mesh Capable of Growing with Cardiac Tissues for Comprehensive Heart Monitoring

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the Ma ...

March 25, 2024

A clinical trial at Cedars-Sinai is testing the safety and efficacy of a device aimed at managing treatment-resistant hypertension. Photo by Getty.

News | Hypertension

Cedars-Sinai Experts Studying Device for Controlling Treatment-Resistant Hypertension

March 18, 2024 — The Smidt Heart Institute at Cedars-Sinai recently became one of four institutions in the U.S. and the ...

March 18, 2024

Visual Thrombus Assessment as presented by Dr. William Gray at the Cardiovascular Research Technologies (CRT) 2024 conference.

News | Left Atrial Appendage (LAA) Occluders

Conformal Medical's CLAAS System Demonstrates Low Thrombogenicity Compared to Commercially Available LAAO Devices

March 18, 2024 — Conformal Medical, Inc. announced that the CLAAS System was featured in a podium presentation at the Ca ...

March 18, 2024

First-of-its-kind trial in US shows drug-coated balloons are a superior treatment option for patients undergoing coronary angioplasty

News | Cardiovascular Clinical Studies

BIDMC-led Trial Leads to FDA approval of Coronary Drug-coated Balloons

March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led ...

March 13, 2024

BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.

News | Heart Failure

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

March 13, 2024